Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04804826 · ClinicalTrials.gov registry record
Same Day Discharge Following Pelvic Reconstructive Surgery
A clinical trial, sponsored by TriHealth.
- Completed
- Registry status
- 54
- Enrollment target
NCT04804826: Completed study, sponsored by TriHealth.
NCT04804826 is a clinical trial that has completed, run by TriHealth. The registered enrollment target is 54 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04804826 has completed, sponsored by TriHealth.
- COMPLETED
- Registry status
- 54 participants
- Enrollment target
Study Summary
This is a prospective cross-sectional study in which patients undergoing major pelvic reconstructive surgery with total vaginal hysterectomy will be recruited and enrolled. At approximately 2 weeks and 12 weeks postoperatively, enrolled patients will be asked to complete a survey detailing their experience with SDD, surgical recovery, and advice for prospective patients.
Primary Outcome
Number of subjects who answered either "Very Satisfied" or "Satisfied" to a Likert scale question "How satisfied are you with the results of your surgery." The liker scale choices are "Very Satisfied", "Satisfied", "Neutral", "Unsatisfied", and "Very Unsatisfied."
Interventions
- PROCEDURE Pelvic Reconstructive Surgery
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2021-06-14 |
| Est. Completion | 2022-04-06 |
What the finished NCT04804826 record still lists
NCT04804826 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 54 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Pelvic Reconstructive Surgery is the first listed.
NCT04804826 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04804826 about?
NCT04804826 is a clinical study titled "Same Day Discharge Following Pelvic Reconstructive Surgery". This is a prospective cross-sectional study in which patients undergoing major pelvic reconstructive surgery with total vaginal hysterectomy will be recruited and enrolled. At approximately 2 weeks and 12 weeks postoperatively, enrolled patients will be asked to complete a survey detailing their exp...
What is the current status of trial NCT04804826?
This trial is currently completed. The enrollment target is 54 participants. The study started on 2021-06-14. Estimated completion is 2022-04-06.
What interventions are being tested in trial NCT04804826?
The interventions under investigation include: Pelvic Reconstructive Surgery (PROCEDURE).
Who is sponsoring clinical trial NCT04804826?
This trial is sponsored by TriHealth, which has 81 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01269853 · 54 participants · Phase 1
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
- NCT02390752 · 54 participants · Phase 1
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- NCT02991248 · 54 participants · NA
Improve Dynamic Lateral Balance of Humans With SCI
- NCT02993900 · 54 participants · NA
Image-Guided Gynecologic Brachytherapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI